Literature DB >> 11720734

The role of the cAMP-PKA system in the short-term regulation of striatal [(14)C]-2-deoxyglucose uptake in freely moving rats.

R Hosoi1, S Momosaki, N Ibii, K Abe, T Itoh, O Inoue.   

Abstract

The cyclic adenosine monophosphate (cAMP)-protein kinase (PK) A system has been shown to have stimulatory effects on glucose utilization in various tissues in vitro. However, little is known about the influence of cAMP on glucose utilization in vivo. In the present study, we examined how cAMP-related compounds affected [(14)C]-2-deoxyglucose (DG) uptake in the striatum of freely moving rats. An intrastriatal injection of dibutyryl-cyclic adenosine monophosphate (db-cAMP), although increasing local cerebral blood flow, was found to decrease the uptake of [(14)C]-2-DG in the striatum. This decrease of [(14)C]-2-DG uptake in the striatum was completely blocked by pretreatment with Rp-adenosine-3',5'-cyclic monophosphorothioate triethylamine (Rp-cAMPS). Moreover, intrastriatal infusion of Rp-cAMPS alone produced a striking increase of [(14)C]-2-DG uptake in the striatum. These results strongly suggest that transient activation of the cAMP-PKA system can depress the glucose phosphorylation process of the rat brain in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720734     DOI: 10.1016/s0006-8993(01)03119-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  2 in total

1.  Effect of rolipram on relative 14C-deoxyglucose uptake in inflammatory lesions and skeletal muscle.

Authors:  Miho Shukuri; Masahiro Terai; Rie Hosoi; Tsunehiko Nishimura; Antony Gee; Osamu Inoue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-15       Impact factor: 9.236

2.  Effects of cAMP-dependent protein kinase activator and inhibitor on in vivo rolipram binding to phosphodiesterase 4 in conscious rats.

Authors:  Tetsuji Itoh; Kohji Abe; Jinsoo Hong; Osamu Inoue; Victor W Pike; Robert B Innis; Masahiro Fujita
Journal:  Synapse       Date:  2010-02       Impact factor: 2.562

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.